You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華大基因(300676.SZ):子公司中標河北省孕婦耳聾基因檢測服務項目
格隆匯 10-26 21:34

格隆匯 10 月 26日丨華大基因(300676.SZ)公佈,公司控股子公司深圳華大臨牀檢驗中心(深圳臨檢)近日收到河北省公共資源交易中心下發的《中標通知書》,通知書確認深圳臨檢為河北省衞生健康委員會2020年-2022年河北省孕婦耳聾基因檢測服務項目(採購編號:Z1300002020631301)的中標單位。此次中標項目預算金額為1.8億元。在項目服務期限內,項目預算金額不超過1.8億元的範圍內,該項目按實際完成的檢測例數進行結算。

遺傳性耳聾基因檢測能夠在分子水平上明確病因、預防遲發性、藥物性耳聾發生、幫助臨牀及時的進行干預、治療和預後評估,在臨牀中具有重要的作用;通過對耳聾高頻基因位點進行檢測,能夠提升聽力障礙的早期發現率,甚至預防部分聽力障礙的發生,從而降低家庭經濟負擔和整體醫療支出,減輕社會負擔。

公司在生育健康基礎研究和臨牀應用服務領域具有多年經驗積累,出生缺陷防控產品佈局廣泛。遺傳性耳聾基因檢測是繼無創產前基因檢測項目後,公司在出生缺陷篩查上的重要佈局之一。新冠疫情期間,公司繼續聚焦主營業務,此次中標及後續實施,有利於進一步拓展遺傳性耳聾基因檢測應用於大樣本量的民生檢測項目,讓精準醫學惠及更多家庭,更大範圍推廣貫穿生命全週期的健康民生實施方案。

此次中標的河北省孕婦耳聾基因檢測服務項目若後續順利實施,將對公司未來經營業績產生一定的積極影響,併為公司後續健康民生項目的推廣提供更多的實施經驗。公司的產品資質、技術、人員等能夠保證該項目的順利履行。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account